NHC CEO Boutin Testifies Before House Energy and Commerce Subcommittee on Drug Pricing
National Health Council Chief Executive Officer Marc Boutin, JD, will testify at 10 a.m. on Wednesday, March 13 at a House Committee on Energy & Commerce Health Subcommittee hearing on “Lowering the Cost of Prescription Drugs: Reducing Barriers to Market Competition” in 2123 Rayburn House Office Building.
The hearing is expected to focus on seven bills designed to make it easier for generic drugs to reach the market, including the CREATES Act, FAST Generics Act, pay-for-delay ban, BLOCKING Act, the FAIR Generics Act, the Orange Book Transparency Act, and Purple Book Continuity Act.
“Over the last few years, I have conducted numerous listening sessions with CEOs of patient organizations, asking them to describe the most significant challenges their constituents currently face,” said Boutin in written testimony submitted to the Subcommittee in advance of the hearing.
“While patient organizations care deeply about driving innovation to help their constituents improve how they feel, function, and survive, they are equally or more concerned about affordable access to high-value care. Even people with life-threatening conditions such as certain types of cancer, neurological, and rare diseases are finding significant access barriers to routine care, and those with historically inexpensive, yet effective, treatments like heart disease have found their costs rising dramatically,” he said.
To read Boutin’s full written testimony, click here.